Development of A Novel Anti-Hyperglycemic Agent

新型抗高血糖药的研制

• 批准号: 7784494
• 负责人: Zhaoping Li
• 金额: --
• 依托单位: VA GREATER LOS ANGELES HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2012-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7784494
• 关键词: Adverse effects; Adverse event; Agreement; Alzheimer' s Disease; Amino Acids; Animal Model; Animals; Asians; Blood; Blood Glucose; Bone Density; Brain; Cardiovascular system; Cause of Death; Cell membrane; Cells; Centers for Disease Control and Prevention (U.S.); Chemistry; Chronic Disease; Clinical; Clinical Trials; Complex; Copper; Country; Cytosol; Defect; Development; Diabetes Mellitus; Diabetes prevention; Dipeptides; Disease; Dose; Double-Blind Method; Drops; Environmental Risk Factor; Enzyme Gene; Enzymes; European; Event; Expenditure; FDA approved; Fasting; Future; Gel; Genes; Genetic; Genetic Polymorphism; Glucagon; Glucose; Glucose Intolerance; Glucose Transporter; Glucose tolerance test; Glycosylated hemoglobin A; Health; Healthcare; Hematology; Hepatic; High Prevalence; Hour; Human; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Impairment; Injection of therapeutic agent; Inpatients; Insulin; Insulin Receptor; Insulin Resistance; Insulinase; Intake; Intestines; Kidney; Lead; Legal patent; Leptin; Literature; Liver; Liver Failure; Marketing; Mediating; Medical; Medical center; Metformin; Molecular; Muscle; Mutation; National Health and Nutrition Examination Survey; Nausea; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Oral; Oral Administration; Outcome; Outcome Study; Outpatients; Patients; Peptide Hydrolases; Peptides; Peripheral; Pharmaceutical Preparations; Pharmacy facility; Phase; Phase I Clinical Trials; Pioglitazone; Placebo Control; Placebos; Plasma; Play; Population; Prevention; Process; Proteins; Randomized; Rattus; Receptor Signaling; Recruitment Activity; Regimen; Reporting; Research; Research Design; Risk; Role; SLC2A1 gene; Safety; Services; Severe Adverse Event; Signal Transduction; Stomach; Sulfonylurea Compounds; Symptoms; Therapeutic Agents; Thyroid Function Tests; Tissues; United States; Urine; Veterans; Visit; Vomiting; Zinc; Zinc deficiency; absorption; adiponectin; analog; base; brain tissue; capsule; commercialization; cost; diabetic; diabetic patient; diet and exercise; effective therapy; experience; fasting plasma glucose; four-arm study; functional disability; glucogenesis; glucose metabolism; glucose output; glucose uptake; glycemic control; histidylproline; improved; inhibitor/antagonist; insulin sensitivity; insulin signaling; novel; oral glucose tolerance; primary outcome; public health relevance; receptor recycling; rosiglitazone; secondary outcome; volunteer; week trial